---
figid: PMC7781009__nihms-1587099-f0001
figlink: pmc/articles/PMC7781009/figure/F1/
number: F1
caption: (A) MET activation is initiated after ligand binding of the hepatocyte growth
  factor (HGF) to the SEMA domain to the extracellular portion of the MET receptor,
  inducing receptor dimerization and phosphorylation of the intracellular domain leading
  to downstream signaling of several pathways. The E3 ubiquitin ligase CBL binds to
  reside Y1003 in the juxtamembrane domain (encoded in part by exon 14), resulting
  in receptor ubiquitination and degradation. MET exon 14 alterations including mutations
  or deletions in splicing regulatory sites, leading to exon skipping, deletion of
  a portion of the juxtamembrane domain, impaired CBL binding, decreased MET turnover,
  and ongoing oncogenic downstream pathway signaling. (B) Point mutations in the tyrosine
  kinase domain result in ligand-independent MET activation through autophosphorylation
  of the tyrosine kinase domain, conveying sustained oncogenic downstream pathway
  signaling. (C) Focal MET amplification leads to higher levels of MET transcription
  and MET expression. MET amplification (high MET/CEP7 ratio) differs from chromosome
  7 polysomy or copy number gain in which the entire chromosome is duplicated (low
  MET/CEP7 ratio). Focal MET amplification and, consequently high MET expression,
  leads to enhanced ligand-independent oncogenic signaling by receptor auto-dimerization
  or oligomerization and auto-phosphorylation. (D) Gene rearrangements involving the
  MET tyrosine kinase domain result in fusion proteins that typically self-dimerize
  in a ligand-independent manner, leading to phosphorylation of the tyrosine kinase
  domain.
pmcid: PMC7781009
papertitle: Targeting MET Dysregulation in Cancer.
reftext: Gonzalo Recondo, et al. Cancer Discov. ;10(7):922-934.
pmc_ranked_result_index: '15156'
pathway_score: 0.8743468
filename: nihms-1587099-f0001.jpg
figtitle: MET oncogenic activation
year: ''
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7781009__nihms-1587099-f0001.html
  '@type': Dataset
  description: (A) MET activation is initiated after ligand binding of the hepatocyte
    growth factor (HGF) to the SEMA domain to the extracellular portion of the MET
    receptor, inducing receptor dimerization and phosphorylation of the intracellular
    domain leading to downstream signaling of several pathways. The E3 ubiquitin ligase
    CBL binds to reside Y1003 in the juxtamembrane domain (encoded in part by exon
    14), resulting in receptor ubiquitination and degradation. MET exon 14 alterations
    including mutations or deletions in splicing regulatory sites, leading to exon
    skipping, deletion of a portion of the juxtamembrane domain, impaired CBL binding,
    decreased MET turnover, and ongoing oncogenic downstream pathway signaling. (B)
    Point mutations in the tyrosine kinase domain result in ligand-independent MET
    activation through autophosphorylation of the tyrosine kinase domain, conveying
    sustained oncogenic downstream pathway signaling. (C) Focal MET amplification
    leads to higher levels of MET transcription and MET expression. MET amplification
    (high MET/CEP7 ratio) differs from chromosome 7 polysomy or copy number gain in
    which the entire chromosome is duplicated (low MET/CEP7 ratio). Focal MET amplification
    and, consequently high MET expression, leads to enhanced ligand-independent oncogenic
    signaling by receptor auto-dimerization or oligomerization and auto-phosphorylation.
    (D) Gene rearrangements involving the MET tyrosine kinase domain result in fusion
    proteins that typically self-dimerize in a ligand-independent manner, leading
    to phosphorylation of the tyrosine kinase domain.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - MET
  - HGF
  - CBL
  - TPR
  - HLA-DRB1
  - PTPRZ1
  - STARD3NL
  - ST7
  - V10921
  - 'N'
genes:
- word: МЕT
  symbol: MET
  source: hgnc_symbol
  hgnc_symbol: MET
  entrez: '4233'
- word: MET
  symbol: MET
  source: hgnc_symbol
  hgnc_symbol: MET
  entrez: '4233'
- word: MET
  symbol: MET
  source: hgnc_symbol
  hgnc_symbol: MET
  entrez: '4233'
- word: МЕT
  symbol: MET
  source: hgnc_symbol
  hgnc_symbol: MET
  entrez: '4233'
- word: MET
  symbol: MET
  source: hgnc_symbol
  hgnc_symbol: MET
  entrez: '4233'
- word: HGF
  symbol: HGF
  source: hgnc_symbol
  hgnc_symbol: HGF
  entrez: '3082'
- word: CBL
  symbol: CBL
  source: hgnc_symbol
  hgnc_symbol: CBL
  entrez: '867'
- word: TPR
  symbol: TPR
  source: hgnc_symbol
  hgnc_symbol: TPR
  entrez: '7175'
- word: HLA-DRB1
  symbol: HLA-DRB1
  source: hgnc_symbol
  hgnc_symbol: HLA-DRB1
  entrez: '3123'
- word: PTPRZ1
  symbol: PTPRZ1
  source: hgnc_symbol
  hgnc_symbol: PTPRZ1
  entrez: '5803'
- word: STARD3NL
  symbol: STARD3NL
  source: hgnc_symbol
  hgnc_symbol: STARD3NL
  entrez: '83930'
- word: ST7
  symbol: ST7
  source: hgnc_symbol
  hgnc_symbol: ST7
  entrez: '7982'
- word: MET
  symbol: MET
  source: hgnc_symbol
  hgnc_symbol: MET
  entrez: '4233'
- word: MET
  symbol: MET
  source: hgnc_symbol
  hgnc_symbol: MET
  entrez: '4233'
- word: МЕТ
  symbol: MET
  source: hgnc_symbol
  hgnc_symbol: MET
  entrez: '4233'
- word: МET
  symbol: MET
  source: hgnc_symbol
  hgnc_symbol: MET
  entrez: '4233'
- word: MET/CEP7
  symbol: MET
  source: hgnc_symbol
  hgnc_symbol: MET
  entrez: '4233'
- word: MET/CEP7
  symbol: MET
  source: hgnc_symbol
  hgnc_symbol: MET
  entrez: '4233'
chemicals:
- word: V10921
  source: MESH
  identifier: C587546
- word: 'N'
  source: MESH
  identifier: D009584
diseases: []
figid_alias: PMC7781009__F1
redirect_from: /figures/PMC7781009__F1
figtype: Figure
---
